Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mauriac, L.
Right arrow Articles by MacGrogan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mauriac, L.
Right arrow Articles by MacGrogan, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:293-298, 2002
© 2002 European Society for Medical Oncology

Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women

L. Mauriac1,+, M. Debled1, M. Durand1, A. Floquet1, V. Boulanger1, C. Dagada1, N. Trufflandier1 and G. MacGrogan2

Departments of 1Medical Oncology and 2Pathology, Institut Bergonié, Regional Cancer Center, Bordeaux, France

Received 25 April 2001; revised 3 August 2001; accepted 27 August 2001.

Background

From 1984 to 1996, 1581 postmenopausal women aged 50–70 years old were treated at Institut Bergonié for an infiltrative non-metastatic breast carcinoma with a positive estrogen and/or progesterone receptor determination.

Patients and methods

Among them, 199 were treated with first line tamoxifen. Ninety-seven had operable disease (T2 >30 mm, T3, N0/1) and 102 had T4 tumours.

Results

After a mean treatment duration of 5.3 months, 89 T2 and T3 (92%) and 93 T4 (91%) were treated by surgery (conservative or not) with or without irradiation, or by irradiation alone. Conserving treatment levels were 53.6% and 44%, respectively. The other women were treated with either second-line chemotherapy or another hormonotherapy; the remaining patients continued regularly with tamoxifen. Overall survival is analysed with a 83 month median follow-up.

Conclusions

A comparison between neoadjuvant endocrine therapy and surgery seems feasible to assess the concept of neoadjuvant hormonotherapy.

Key words: locally advanced breast cancer, neoadjuvant endocrine therapy, operable breast cancer, postmenopausal women


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Mustacchi, M. Mansutti, C. Sacco, S. Barni, A. Farris, M. Cazzaniga, M. Cozzi, and C. Dellach
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
Ann. Onc., April 1, 2009; 20(4): 655 - 659.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Mustacchi, R. Ceccherini, S. Milani, A. Pluchinotta, A. De Matteis, L. Maiorino, A. Farris, A. Scanni, and F. Sasso
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial
Ann. Onc., March 1, 2003; 14(3): 414 - 420.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.